Journal article icon

Journal article

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.

Abstract:

AIM: Effective type 2 diabetes management requires a multifactorial approach extending beyond glycaemic control. Clinical practice guidelines suggest targets for HbA1c, blood pressure and lipids, and emphasize weight reduction and avoiding hypoglycaemia. The phase 3 clinical trial programme for liraglutide, a human glucagon-like peptide 1 analogue, showed significant improvements in HbA1c and weight with a low risk of hypoglycaemia compared to other diabetes therapies. In this context, we pe...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM, Biomedical Research Centre
Role:
Author
Journal:
Diabetes, obesity and metabolism
Volume:
14
Issue:
1
Pages:
77-82
Publication date:
2012-01-05
DOI:
EISSN:
1463-1326
ISSN:
1462-8902
URN:
uuid:12920ab4-a744-4cb1-9a46-6a675b5add42
Source identifiers:
175156
Local pid:
pubs:175156

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP